Revolutionary Diabetic Ulcer Treatment Headed to Market
- Thu, 6/14/12 - 2:44pm
- 0 Comments
- 517 reads
MxBiodevices (Greenville, NC) biotech company has received a $30,000 Company Inception Loan from the North Carolina Biotechnology Center to aid in completing its business plan for it new treatment for diabetic foot ulcers (DFU).
The technology behind the company is a synthetic nanofiber scaffold that is injected under the ulcer bed which provides a healing environment for the patient’s own cells to initiate tissue regeneration. In contrast, current wound care products are topical applications that do not treat the underlying tissue. The technology has proven to be effective in a broad array of applications, including: tendon, bone and dermal wound repair, cosmetic surgery, and dental applications.
The next steps for the company will be to gain approval to treat DFUs in the US and Europe. Manufacturing capabilities are already in place and the technology has previously been approved for use for several applications in both the US and Europe. In place regulatory approvals, DFU clinical data and product manufacturing agreements will speed commercialization; current plans anticipate arrival in the European market in 2013 and in the US market within 3 years.